Status:
COMPLETED
Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Malignant Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A prospective feasibility trial initially including 10 patients to investigate if Neurofilament light protein can be detected in peripheral blood in patients undergoing Isolated Limb Perfusion with ch...
Detailed Description
In isolated limb perfusion (ILP) neurotoxicity is a known side effect, this is in spite of the fact that a relatively mild hyperthermic temperature is used which should be well tolerated by the nerves...
Eligibility Criteria
Inclusion
- Patient scheduled for treatment with isolated limb perfusion
- Age over 18 years
- Signed informed consent
Exclusion
- None
Key Trial Info
Start Date :
April 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 25 2020
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04460053
Start Date
April 12 2019
End Date
October 25 2020
Last Update
April 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sahlgrenska University Hospital
Gothenburg, Sweden, 413 45